Literature DB >> 12631235

A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain.

José Ronnie C Vasconcelos1, Silvia B Boscardin, Meire I Hiyane, Sheila S Kinoshita, Adriana E Fujimura, Mauricio M Rodrigues.   

Abstract

BALB/c or C57Bl/6 mice immunized with plasmids containing Trypanosoma cruzi genes developed specific immune responses and protective immunity against lethal parasitic infection. In contrast, in the highly susceptible mouse strain A/Sn, DNA vaccination reduced the peak parasitemia but promoted limited mouse survival after challenge. In the present study, we tested whether the immunogenicity and protective efficacy of vaccination could be improved by combining DNA and recombinant protein immunization regimens. A/Sn mice immunized with plasmid p154/13 which harbours the gene encoding Trypanosoma cruzi trans-sialidase developed a predominant type 1 immune response. In contrast, immunization with the recombinant Trypanosoma cruzi trans-sialidase protein adsorbed to alum generated a typical type 2 immune response. Simultaneous administration of both p154/13 and recombinant Trypanosoma cruzi trans-sialidase protein also led to a predominant type 2 immune response. Sequential immunization consisting of two priming doses of p154/13 followed by booster injections with recombinant Trypanosoma cruzi trans-sialidase protein significantly improved specific type 1 immune response, as revealed by a drastic reduction of the serum IgG1/IgG2a ratio and by an increase in the in vitro interferon-gamma secretion by CD4 T cells. Our observations confirm and extend previous data showing that a DNA-priming protein-boosting regimen might be a general strategy to enhance type 1 immune response to DNA vaccines. Upon challenge with Trypanosoma cruzi, no improvement in protective immunity was observed in mice immunized with the DNA-priming protein-boosting regimen when compared to animals that received DNA only. Therefore, our results suggest that in this experimental model there is no correlation between the magnitude of type 1 immune response and protective immunity against Trypanosoma cruzi infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631235     DOI: 10.1046/j.0818-9641.2002.01136.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  12 in total

1.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

3.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

4.  Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.

Authors:  G Salay; M L Dorta; N M Santos; R A Mortara; C Brodskyn; C I Oliveira; C L Barbiéri; M M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2007-07-11

5.  Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.

Authors:  Vandanajay Bhatia; Nisha Jain Garg
Journal:  Clin Vaccine Immunol       Date:  2008-06-11

6.  Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.

Authors:  Raquel T Nogueira; Alanderson R Nogueira; Mirian C S Pereira; Maurício M Rodrigues; Ricardo Galler; Myrna C Bonaldo
Journal:  Virol J       Date:  2011-03-18       Impact factor: 4.099

Review 7.  Experimental Vaccines against Chagas Disease: A Journey through History.

Authors:  Olivia Rodríguez-Morales; Víctor Monteón-Padilla; Silvia C Carrillo-Sánchez; Martha Rios-Castro; Mariana Martínez-Cruz; Alejandro Carabarin-Lima; Minerva Arce-Fonseca
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

8.  Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.

Authors:  Anitra L Farrow; Girish Rachakonda; Linlin Gu; Valentina Krendelchtchikova; Pius N Nde; Siddharth Pratap; Maria F Lima; Fernando Villalta; Qiana L Matthews
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

9.  TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

10.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.